Veterinary Intravenous (IV) Solutions Market Report 2026

The veterinary intravenous (iv) solutions market size has grown strongly in recent years. It will grow from $1.62 billion in 2025 to $1.75 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to rising prevalence of dehydration and electrolyte imbalances in animals, growth in companion animal population, increasing number of veterinary hospitals and clinics, adoption of conventional iv solutions, technological advancements in veterinary fluid therapy.

The veterinary intravenous (iv) solutions market size is expected to see strong growth in the next few years. It will grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growing demand for advanced isotonic and colloid solutions, increasing adoption of parenteral nutrition in veterinary care, development of specialized iv solutions for critical care, rising awareness of fluid therapy benefits, expansion of veterinary emergency and critical care services. Major trends in the forecast period include development of advanced isotonic and balanced electrolyte solutions, increased use of synthetic and natural colloids, growth in parenteral nutrition solutions for companion and production animals, adoption of pre-mixed and ready-to-use iv solutions, expansion of veterinary critical care and emergency fluid therapy.

The rising prevalence of various animal diseases is expected to drive the growth of the veterinary intravenous (IV) solutions market going forward. Animal diseases include conditions or disorders that impair the health and functioning of animals, with common examples being anthrax, leptospirosis, rabies, canine distemper, heartworm disease, and more. The increase in disease prevalence is driven by factors such as intensive farming practices, wildlife encroachment, and antibiotic resistance. Veterinary intravenous solutions play a crucial role in rehydrating animals affected by dehydration-inducing diseases, such as gastroenteritis or severe infections, by ensuring optimal hydration and supporting overall health outcomes. For example, in May 2025, according to the World Organisation for Animal Health (WOAH), a France-based intergovernmental animal health body, outbreaks of avian influenza in mammals more than doubled compared with 2023, with 1,022 reported outbreaks across 55 countries compared to 459 outbreaks in 2023, reflecting a significant rise in disease prevalence across multiple species. Therefore, the increasing prevalence of animal diseases is driving the growth of the veterinary intravenous (IV) solutions market.

Rising expenditure on animal health products is also expected to propel the growth of the veterinary intravenous (IV) solutions market. Animal health products include medications, supplements, and treatments aimed at maintaining or improving animal health. The rise in spending on these products is driven by factors such as increased pet ownership, greater awareness of animal health, advancements in veterinary care, and the need for improved disease prevention and treatment. Veterinary IV solutions contribute to this trend by addressing urgent medical needs and enhancing veterinary care. For example, the Republic of Estonia Agency of Medicines reported in March 2024 that the veterinary medicinal products market grew by 6.9% in 2023, reaching $20.54 million (18.6 million euros), up from $19.21 million (17.4 million euros) in 2022. This increase in spending on animal health products is driving the growth of the veterinary IV solutions market.

Leading companies in the veterinary IV solutions market are focusing on developing advanced products, such as fluoroquinolone antibiotics, to enhance efficacy and safety. Fluoroquinolones are a potent class of antibiotics used in both human and veterinary medicine to treat a variety of bacterial infections, with careful management to prevent resistance and side effects. For example, in April 2024, Elanco, a US-based pharmaceutical company, introduced Pradalex, a pradofloxacin injection solution approved by the US Food and Drug Administration (FDA). This 3rd generation fluoroquinolone is approved for treating swine respiratory disease (SRD) caused by several pathogens, including Bordetella bronchiseptica, Glaesserella (Haemophilus) parasuis, Pasteurella multocida, streptococcus suis, and mycoplasma hyopneumoniae. The drug's label advises that it should be used only after other non-fluoroquinolone treatment options have been considered.

Major companies operating in the veterinary intravenous (iv) solutions market are Merck & Co. Inc., Baxter International Inc., Zoetis Inc., Fresenius Kabi AG, Elanco Animal Health Incorporated, B. Braun Melsungen AG, Virbac SA, Dechra Pharmaceuticals PLC, Vetoquinol SA, Norbrook Laboratories Limited, Ceva Santé Animale, Revival Animal Health Inc., Aromor Animal Health, Jorgensen Laboratories LLC, Pharmacosmos AS, Sykes Veterinary International Pty Ltd., Rusoma Laboratories Private Limited, Patterson Companies Inc., NexGen Veterinary, Soxa Formulations & Research Pvt. Ltd.

North America was the largest region in the veterinary intravenous (IV) solutions market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary intravenous (iv) solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary intravenous (iv) solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the veterinary intravenous (IV) solutions market by increasing the cost of imported IV fluids, colloids, and parenteral nutrition components, affecting pricing and availability for veterinary hospitals and clinics. Segments such as isotonic crystalloids, synthetic colloids, and parenteral nutrition are most affected, particularly in regions like North America and Europe dependent on imports. However, tariffs have also encouraged local manufacturing and development of cost-effective IV solutions, creating opportunities for domestic producers and enhancing regional supply resilience.

The veterinary intravenous (iv) solutions market research report is one of a series of new reports that provides veterinary intravenous (iv) solutions market statistics, including veterinary intravenous (iv) solutions industry global market size, regional shares, competitors with a veterinary intravenous (iv) solutions market share, detailed veterinary intravenous (iv) solutions market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary intravenous (iv) solutions industry. This veterinary intravenous (iv) solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary intravenous (IV) solutions are sterile fluids administered directly into an animal’s bloodstream through a vein, usually via an IV catheter. These solutions are used in veterinary care to treat dehydration and electrolyte imbalances, deliver medications, or provide essential nutrients. They are crucial for maintaining or restoring fluid and electrolyte balance in animals, particularly during illness, surgery, or trauma.

The main types of veterinary intravenous (IV) solutions include isotonic crystalloids, dextrose solutions, synthetic colloids, natural colloids, and parenteral nutrition. Isotonic crystalloids are IV fluids with a solute concentration equal to that of the blood, helping to maintain fluid balance. These solutions are applicable to various animal types, including companion animals and production animals. They are used by different end-users such as veterinary hospitals and clinics, research institutes, and other related entities.

The veterinary intravenous (IV) solutions market consists of sales of hypertonic solutions, isotonic solutions, and hypertonic solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.